Active Ingredient History
Reserpine is an alkaloid, isolated from the Rauwolfia serpentina plant and developed by Ciba pharma. Reserpine was approved by FDA for the treatment of hypertension and psychotic disorders. The drug exerts its effect by blocking two vesicular monoamine transporters, VMAT1 and VMAT2. The blockade results in vesicles that lose their ability to store neurotransmitter molecules. Neurotransmitters, thus retained in cytosol, are then neutralized by MAO. NCATS
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Hypertension (approved 1955)
Psychotic Disorders (approved 1955)
Amphetamine-Related Disorders (Phase 1)
Cardiovascular Diseases (Phase 3)
Cerebrovascular Disorders (Phase 3)
Cocaine-Related Disorders (Phase 2)
Heart Diseases (Phase 3)
Hypertension ()
Hypertension, Pulmonary (Phase 1)
Substance-Related Disorders (Phase 2)
Vascular Diseases (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue